JNJ submits sNDA for Xarelto in ACS: http://finance.yahoo.com/news/Janssen-Research-Development-prnews-2281138537.html?x=0 For the reasons mentioned in #msg-69172520, I don’t expect Xarelto to have any impact on Lovenox sales in this particular indication.